1601 TRAPELO ROAD, WALTHAM, MA
Life Can Only Be Understood Backwards; But It Must Be Lived Forwards… Kierkegaard 1
U.S. IND Clearance and Alignment with U.S. FDA on Pivotal Clinical Program for VYD2311, a Vaccine-Alternative Antibody to Prevent COVID
Appoints Paul B. Bolno, M.D. to Its Board of Directors
Announces Closing of $57.5 Million Public Offering and Full Exercise of the Underwriter’s Option to Purchase Additional Shares
Invivyd and Researchers Launch SPEAR Study for Long COVID Therapy
Invivyd Announces Positive Phase 1/2 Data for COVID-19 Monoclonal Antibody VYD2311
Submission of Matters to a Vote of Security Holders
Financial Results, Other Events
Q2
Q1
FY 2024
Q3
FY 2023
Registration Statement for Securities Offered under a Shelf Registration
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Securities to be Offered to Employees
Effectiveness Notice
Notice of Exempt Offering of Securities
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Definitive Additional Proxy Soliciting Materials
Definitive Additional Information Statement
Statement of Changes in Beneficial Ownership
Initial Statement of Beneficial Ownership
Notice of Proposed Sale of Securities
Free Writing Prospectus